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Background: RBM10 is an RNA binding protein involved in the regulation of transcription, alternative splicing and
message stabilization. Mutations in RBM10, which maps to the X chromosome, are associated with TARP syndrome,
lung and pancreatic cancers. Two predominant isoforms of RBM10 exist, RBM10v1 and RBM10v2. Both variants have
alternate isoforms that differ by one valine residue, at amino acid 354 (RBM10v1) or 277 (RBM10v2). It was recently
observed that a novel point mutation at amino acid 354 of RBM10v1, replacing valine with glutamic acid, correlated
with preferential expression of an exon 11 inclusion variant of the proliferation regulatory protein NUMB, which is
upregulated in lung cancer.
Findings: We demonstrate, using the GLC20 male-derived small cell lung cancer cell line - confirmed to have only
one X chromosome - that the two (+/−) valine isoforms of RBM10v1 and RBM10v2 result from alternative splicing.
Protein modeling of the RNA Recognition Motif (RRM) within which the alteration occurs, shows that the presence
of valine inhibits the formation of one of the two α-helices associated with RRM tertiary structure, whereas the
absence of valine supports the α-helical configuration. We then show 2-fold elevated expression of the transcripts
encoding the minus valine RBM10v1 isoform in GLC20 cells, compared to those encoding the plus valine isoform.
This expression correlates with preferential expression of the lung cancer-associated NUMB exon 11 inclusion variant.
Conclusions: Our observations suggest that the ability of RBM10v1 to regulate alternative splicing depends, at least in
part, on a structural alteration within the second RRM domain, which influences whether RBM10v1 functions to support
or repress splicing. A model is presented.
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Background
The RNA binding protein RBM10 is capable of regulat-
ing the expression of a number of genes including some
involved in apoptosis (e.g., FASR) [1] and cell prolifera-
tion (e.g., NUMB) [2]. In all of the reported cases but
one, this expression regulation takes the form of alterna-
tive splicing regulation [1-4]. The one gene whose ex-
pression is not regulated by RBM10-mediated alternative
splicing is the angiotensin receptor 1 (AT1), where RBM10
influences AT1 expression by binding within the transcript’s* Correspondence: lsutherland@amric.ca
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unless otherwise stated.3′-untranslated region (UTR), stabilising the message and
subsequently contributing to a decreased rate of transcrip-
tion [4]. How RBM10 accomplishes these disparate func-
tions remains to be determined.
The region(s) within the RBM10 protein that is in-
volved in any of the RNA-protein interactions identified
to date has not been defined although it likely involves
at least one of two RNA Recognition Motifs (RRM) and
two zinc fingers (ZnF) [5]. On the other hand, two con-
sensus motifs within the target RNA with which the
RBM10 protein binds have been defined as CUCUGAA
CUC and CGAUCCCU [2]. Using HeLa cells, Bechara
et al. [2] reported that RBM10 interactions occurred pre-
dominantly within the upstream intron of an excluded
alternate exon but predominantly downstream of an in-
cluded alternate exon. On the other hand, using HEK293
cells, Wang et al. [3] reported that RBM10 interactionsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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within both the upstream and downstream introns of
alternate exons, though predominant binding in the vicin-
ity of the upstream 3′-splice site was associated with less
exon skipping. Obviously, much remains to be elucidated
concerning the regulation of these interactions.
Mutations in RBM10 have been noted in cells associated
with lung and pancreatic cancers and the neuromuscular
disorder TARP syndrome [3,6-10] (summarized in Table 1).
In one lung study, 12/183 (7%) adenocarcinoma speci-
mens had RBM10 mutations, each patient having a differ-
ent mutation (5/12 being missense, 5/12 truncating and
2/12 splice-site) [10]. In another lung study, a mutation -
caused by a T to A substitution and consequent valine (V)
to glutamic acid (E) substitution within the second RRM
(RRM2) of RBM10 - was reported in A549 lung adeno-
carcinoma cells, with consequences for NUMB alternative
splicing [2]. In the blood cells of patients with TARP syn-
drome, six different mutations were identified [6-8], and a
six exon-spanning deletion (aa 651–889) that codes for a
truncated RBM10 isoform with an inability to regulate
alternative splicing [3].
The pre-mRNA for RBM10 is alternatively spliced to
yield two predominant protein isoforms: a 930 amino
acid (aa) (~103.5 kDa) isoform that includes exon 4, re-
ferred to as RBM10 variant 1 (RBM10v1), and an 853 aa
(~94.5 kDa) isoform that lacks exon 4, referred to asTable 1 RBM10 mutations
Phenotype Mutation effect Mutation
NSCLC Missense
NSCLC Missense








TARP syndrome Nonsense c.1235G>A
NSCLC Missense
NSCLC Splice site
Pancreatic neoplasm Frameshift c.1817-1818insA
TARP syndrome Frameshift c.1893-1894insA




NSCLC Splice siteRBM10v2. In addition to the two major RBM10 variants,
the Ensembl Database lists a variant of RBM10v2 that is
one amino acid shorter (852 aa). The 7 April 2003 Gen-
Bank deposition version 1 for this RBM10v2(V277del)
isoform (NM_152856.1) describes it as having an “alter-
nate donor splice site” compared to RBM10v1. Indeed, a
tandem donor splice site of the configuration GYNGYN
was identified in RBM10 exon 10 (as GTGGTG) from a
screen of expressed sequence tags (ESTs) for variants
generated from upstream and downstream tandem re-
peat triplets [11]. Utilization of the downstream triplate
(the “e” site referred to in [11]) would result in the inclu-
sion of a valine at amino acid 277 for RBM10v2 and 354
for RBM10v1. For clarity throughout this manuscript, we
will refer to the longer RBM10v2 isoform as RBM10v2
(V277), the shorter RBM10v2 isoform as RBM10v2
(V277del), the longer RBM10v1 isoform as RBM10v1
(V354) and the shorter RBM10v1 isoform as RBM10v1
(V354del).
Our comprehensive review of the literature and vari-
ous protein databases suggested that the presence of
RBM10v1(V354del) is by no means generally recognized
and that there appears to be some confusion as to its
legitimacy and the mechanism by which it is generated.
For instance, RBM10v1(V354del) has been identified as
RBM10 “missing” valine 354 (UniProt – P98175-2), and
as a mismatch of I353 with valine (on the Protein DataExon Protein Reference
2 E4K Imielinski et al. [10]
2 R6H Imielinski et al. [10]
3 p.Lys54SerfsX80 Gripp et al. [7]
3 E67 Imielinski et al. [10]
4 p.Gln150X Johnston et al. [8]
5 R157fs Imielinski et al. [10]
7 Y206 Imielinski et al. [10]
8 R230 Imielinski et al. [10]
8 Johnston et al. [8]
10 1316F Imielinski et al. [10]
12 p.Trp412X Johnston et al. [6]
16 Y580F Imielinski et al. [10]
17 Y596 Imielinski et al. [10]
17 p.E606EfsX37 Furukawa et al. [9]
17 p.Pro632ThrfsX41 Johnston et al. [6]
18-23 Wang et al. [3]
18 R685L Imielnski et al. [10]
20 p.Arg726X Johnston et al. [8]
21 E810 Imielinski et al. [10]
22 V846 Imielinski et al. [10]
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scribed in various databases and references, see Table 2.
In the study presented herein using a small cell lung
cancer cell line, we confirm the existence of two full-length
RBM10v2 transcripts, RBM10v2(V277) and RBM10v2
(V277del), and prove the existence of two full-length
RBM10v1 transcripts, RBM10v1(V354) and RBM10v1
(V354del). We then demonstrate that the presence or
absence of valine alters the tertiary structure of the second
RNA Recognition Motif (RRM2) within the RBM10 pro-
tein. Finally, we show that 2-fold higher levels of the tran-
scripts encoding the minus - compared to the plus - valine
isoforms of both RBM10v1 and RBM10v2 correlates with
higher levels of the lung cancer associated NUMB exon 11
inclusion variant, compared to the exon 11 exclusion
variant.
Results
Evidence that alternative splicing occurs within exon 10
The GLC20 cell line was established from a small cell
lung cancer (SCLC) of male origin [12]. It is RBM5-
null and was determined, by FISH, to contain only one
X chromosome (Figure 1A). Alternative splicing of the
X-linked RBM10 gene [13], to generate both RBM10v1
and RBM10v2, was confirmed in the GLC20 cells, using
RT-PCR (Figure 1B). Most of the cancer, or transformed,
cell lines that we have tested express more RBM10v1 than
RBM10v2, at both the mRNA (Figure 1B) and protein





NIH GenBank STIVEAA NM_005676
STIEAA NM_001204467
NIH GenBank STIVEAA NP_005667
STIEAA NP_001191396
EMBL-EBI InterPro STIVEAA P98175
UniProtKB STIVEAA P98175-1
STI-EAA P98175-2




HUGE STI-EAA KIAA0122/GenBank D50912
References
Bechara et al. [2] Minus valine isoform;
STI(E)EAA
Inoue et al. [1] STI-EAA KIAA0122particularly true for GLC20 cells, which express such a
small amount of RBM10v2 protein that it is technically
challenging to detect.
To estimate functionality of RBM10 in the GLC20
cells, sequencing of cDNA was carried out. Only full-
length RBM10v1 cDNA was sequenced because full-
length RBM10v2 cDNA could not be amplified from the
GLC20 cells. Mixed sequence was observed beginning at
the 3′-end of exon 10, with either the forward or reverse
primer. At that point in time (June 2014), the Ensembl
Database listed two different RBM10v2 isoforms, we are
herein designating RBM10v2(V277) and RBM10v2(V277del)
(corresponding to GenBank Accession Numbers NM_
001204466.1 and NM_152856.2). To determine if the
mixed sequencing read in the GLC20 RBM10v1 sample
was the result of a mixture of transcripts with different
exon 10 3′-end sequences, we designed primers immedi-
ately 3′- to the anticipated modified triplet site in the
cDNA (refer to Figure 1D for primer locations), thereafter
expecting an unambiguous sequence read. Indeed, clear
sequence was obtained, thereby delineating the altered re-
gion as the last three nucleotides of exon 10 (Figure 1E).
The presence of a mixture of two different isoforms of
RBM10v1 suggested either an alternative splicing event
or two RBM10 alleles, the later possibility being unlikely
since we had confirmed only one X chromosome by
FISH analysis (Figure 1A). Since there remained the pos-
sibility of an RBM10 gene duplication with allelic vari-
ation, we decided to sequence RBM10v1 cDNA from
additional cell lines, theorizing that if the same mixed
read was observed in other cells it would suggest alter-
native splicing. We sequenced transcripts from both
male and female-derived cell lines, since one RBM10
allele is silenced as the result of X chromosome inactiva-
tion in female somatic cells [14,15], therefore whether
male or female-derived, cell lines would theoretically
have only one RBM10 gene that is transcribed. RBM10v1
and RBM10v2 cDNA was sequenced in A549 (a male-
derived lung adenocarcinoma cell line), HeLa (a female-
derived cervical adenocarcinoma cell line) and BEAS-2B
(a male-derived non-cancerous SV40/adenovirus-transformed
lung cell line). Sequencing data revealed the same nucleotide
variation in exon 10 of RBM10v1 and exon 9 of RBM10v2 in
all three cell lines, therefore suggesting that the two isoforms
of RBM10v1 are, as originally surmised within GenBank
deposition NM_152856.1 and by Hiller et al. [11], the
result of an alternative splicing event. An example of
how this might occur is presented diagrammatically
in Figure 1F.
Sequence variation that occurs as a result of alterna-
tive splicing at the 3′-ends of exons with tandem repeats
such as GYNGYN, is regulated partly by U1snRNA
binding and partly by the presence of CGGG and GGGT
sequons in the downstream intron, particularly if the
Figure 1 Alternative splicing of RBM10. (A) FISH analysis of GLC20 cells, with painted X and Y chromosomes, demonstrating the presence of
only one X chromosome. (B) RBM10v1 and RBM10v2 RNA expression in various cell lines, including GLC20. Representative raw RT-PCR data using
RBM10 exon 4 spanning primers. Bi: RBM10F with RBM10RS primers. Bii: RBM10F with RBM10v1/v2R primers. M: 100 bp DNA ladder (FroggaBio
Inc., Toronto, Canada). NTC: no template control. (C) Protein expression by Western blot. Ci shows RBM10 expression in whole cell lysates from
three cell lines, including GLC20. The numbers 1, 2 and 3 after JKM1 and GLC20 delineate cells from three biological replicates. Cii includes control
HeLa protein and in vitro translated RBM10v1 and RBM10v2 protein, to confirm the location of RBM10v2 is the cell line extracts. (D) Cartoon of
full-length RBM10v1 mRNA, not drawn to scale. Boxes represent exons. Left and right black arrows represent primer placement for sequencing.
Approximate positioning of consensus functional motifs is indicated by text and differential shading. (E) Alignment of the two GLC20 RBM10v1
isoform sequences. Circled area indicates the region that differs between the two RBM10v1 isoforms. (F) Nucleotide and amino acid sequences of
the RBM10v1 exon10/intron 10/exon 11 donor and acceptor sites for (i) RBM10v1(V354), and (ii) RBM10v1(V354del).
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[11]. Intron 10 of RBM10 is 171 nts and contains three
CGGG sequons, two GGGT sequons and one CGGGGT
sequon, suggesting that co-expression of the two RBM10v1
isoforms is indeed a regulated alternative splicing event.
The stimuli that control this regulation remain to be de-
termined, but are unlikely limited to male, lung or cancer
cells, since both RBM10v1(V354) and RBM10v1(V354del)
were present in A549, HeLa, BEAS-2B and GLC20 cells.
Structural consequences of alternative splicing of RBM10v1
RBM10v1 and RBM10v2 both contain two RRMs (refer
to Figure 1D) defined as ~75-85 amino acids that three
dimensionally form four β-sheets flanked by two α-
helices. The most conserved sequences within any RRM
comprise the RNP2 and RNP1 domains (reviewed in
[5]), RNP1 having the most highly conserved sequence
of the two. Notably, amino acid 354 in RBM10v1 is lo-
cated in approximately the middle of RRM2, at the begin-
ning of the second α-helix and near to the end of β-sheet
three, which is encoded by the highly conserved RNP1
domain [16].
Valines have a high free energy that is associated with
α-helix disruption and since α-helices are known to con-
tribute to the stabilization of RNA/protein interactions,
disruption of the α-helix by a valine insertion would be
predicted to destabilize any RNA/protein interaction. In
RBM10, the placement of the altered amino acid adjacent
to the highly conserved β-sheet three structure suggested
that any potential alteration to the second α-helical struc-
ture within RRM2 might have a significant effect on over-
all protein conformation, and consequently, the ability to
interact with RNA. Indeed, Bechara et al. [2] recently de-
scribed a G to T mutation in the terminal exon 10 codon
of RBM10, which changed the amino acid coded from
valine (V) to a glutamic acid (E). This single mutation had
dramatic functional consequences, manifesting as an
altered ability to splice specific downstream targets, such
as pre-mRNA encoding the proliferation regulatory pro-
tein NUMB [2].
To better understand how a change to this residue
might contribute to RBM10 functional alterations we
compared the structures of a valine-retaining, a glutamic
acid-substituting and a valine-lacking amino acid within
RRM2. We uploaded these altered RBM10v1 RRM2 se-
quences into SwissProtKB/Swiss-Prot (www.expasy.org),
a program that predicts a two-dimensional configuration
and ranks it against similar configurations of previously
crystalized structures. A crystal structure for a minus-
valine RBM10 RRM2 (designated 2m2d) [17,18] was the
reference structure for the V354, V354E and V354del
RBM10v1 RRM2 predictions. We also uploaded the RRM2
sequences into Phyre2 (the Protein Homology/analogY Rec-
ognition Engine v2.0, www.sbg.bio.ic.ac.uk). To visualize arotatable three-dimensional structure, the structure pre-
dictions for V354, V354E and V354del from both Swiss
ProtKB and Phyre2 were uploaded into the Yasara mod-
eling program (Yet Another Scientific Artificial Reality
Application, www.yasara.org). A comparison of all the
predictions (Figure 2) revealed that the addition of
valine did, as anticipated, disrupt the α-helical structure
and thus the classic configuration of an RRM domain
(shown as a colour change from dark blue to cyan by
the Yasara software). Exclusion of the valine was associ-
ated with an α-helix. Substitution of the V for an E re-
sulted in two slightly different configurations, depending
on the prediction program used: both programs, however,
predicted a change to, but a retention of, an α-helical
structure compared to either the V354del or the V354.
These modelling results suggest that conformational
changes to the RBM10v1 protein could be responsible for
altering the protein’s ability to interact with RNA.
Functional consequences of alternative splicing of RBM10v1
Using PAR-CLIP technology Bechara et al. [2] identified
an RBM10 cluster in the 3′-splice site region preceding
NUMB exon 11 (the current Ensembl exonic designation
for the previously referred to NUMB exon 9) [2]. They
then went on to demonstrate, using an A549 non-small
cell lung cancer (NSCLC) cell line with an RBM10v1
(V354E) mutation (herein referred to as A549-JV), that
expression of recombinant RBM10v1 protein, with either
a valine or a glutamic acid at amino acid 354, altered
NUMB splicing. With valine present (RBM10v1(V354)),
there was preferential NUMB exon 11 exclusion - asso-
ciated with NOTCH repression and decreased prolifera-
tion. On the other hand, the glutamic acid-containing
isoform (RBM10v1(V354E)) demonstrated preferential
NUMB exon 11 inclusion – associated with NOTCH ac-
tivation and increased proliferation. Recognising that a
V354E substitution would not necessarily have a similar
effect as a V354del, but taking into consideration our
structural predictions, the fact that the valine to glu-
tamic acid mutation occurred at exactly the same site as
the RBM10v1 alternative splicing of RBM10v1(V354) to
RBM10v1(V354del) suggested to us that regulated alter-
native splicing of RBM10v1 has functional significance
and is important to lung cancer.
Considering that RBM10v1(V354) expression corre-
lated with preferential NUMB exon 11 exclusion and
RBM10v1(V354E) expression correlated with preferen-
tial NUMB exon 11 inclusion [2] and that expression of
the exon 11 retaining NUMB transcript is frequently in-
creased in lung adenocarcinomas [19], one might predict
that (a) downregulation of RBM10v1(V354) is one means
by which lung cancer cells circumvent proliferation con-
trols, and (b) more RBM10v1(V354del) than RBM10v1
(V354) is expressed in lung cancers. Interestingly, we have
Figure 2 Conformation of RBM10v1 RRM2. The RBM10 RRM2 conformation was modeled using SwissProtKB (A) or Phyre2 (B). (i) Isoforms
V354. (ii) Isoforms V354E. (iii) Isoforms V354del. Arrow indicates the position of the +/− valine. Yasara structure colors indicate beta-sheets (red),
alpha-helixes (dark blue), turns (green) and random coils (cyan).
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aration) demonstrating that in the GLC20 small cell lung
cancer cells and three stable GLC20 sublines, transcripts
encoding RBM10v1(V354del) and RBM10v2(V277del)
have ~2-fold higher expression than transcripts encod-
ing RBM10v1(V354) and RBM10v2(V277) (Figure 3A).
When NUMB exon 11 alternative splicing was examined
in the GLC20 cells, as predicted, preferential expression
of the NUMB exon 11 inclusion variant was observed
(Figure 3B).
NUMB splicing was also examined in HeLa and
BEAS-2B cells as well as our A549 cells (herein referred
to as A549-LS) that, unlike those used by Valcárcel andcolleagues [2], express transcripts encoding both RBM10v1
(V354) and RBM10v1(V354del), as opposed to only
RBM10v1(V354E). If RBM10v1(V354del) functions in a
similar manner to RBM10v1(V354E) - to generate the
NUMB exon 11 inclusion transcript - then we anticipated
A549-LS cells would express both the NUMB exon 11 in-
clusion and exclusion transcripts. We also anticipated
more of the NUMB exon 11 exclusion transcript in the
A549-LS cells (resulting from RBM10v1(V354) expres-
sion), compared to the A549-JV subline (which lacks
RBM10v1(V354)). As shown in Figure 3B, and confirm-
ing the observations of Valcárcel and colleagues [2], the
A549-LS subline expressed both NUMB variants, but
Figure 3 Functional affects associated with RBM10 variant expression. (A) In GLC20 cells, comparative expression levels of RBM10v1 and
RBM10v2 transcripts encoding the valine-retaining and valine-lacking isoforms, as determined by RNA-seq. *p < 0.05. (B) NUMB alternative splicing
in A549, HeLa, BEAS-2B and GLC20 cells. (i) and (ii) are 2% agarose gels with SYBR®safe, showing representative amplicon expression levels following
end-point PCR with (i) 28 cycles, or (ii) 40 cycles, using NUMB exon 11-spanning primers and (i) 19 cycles or (ii) 25 cycles for GAPDH. (iii) Following
densitometry of amplicons from six end-point PCR reactions (three at 28 cycles and three at 40 cycles) of the two different cDNA preparations from
one RNA extraction for each cell line, the percentage of the NUMB exon 11 exclusion variant was calculated and plotted. Error bars represent the
standard error of the mean. Significances were calculated using an unpaired Student’s t-test, with *p < 0.05, **p < 0.01 and ****p < 0.0001. (C) Model
depicting how the +/− valine isoforms of RBM10v1 might influence NUMB exon 11 alternative splicing. The plus and minus valine isoforms are present,
at low levels, in normal cells, and contribute to the production of both the exon 11 inclusion and exclusion variants of NUMB. Both RBM10 isoforms are
able to bind NUMB pre-mRNA, but the minus valine isoform of RBM10v1 does so with higher affinity, having the classical α-helix structure. The plus
valine isoform does not bind as efficiently, thereby interfering with recognition of the intron 10 3′splice site, resulting in NUMB exon 11 exclusion.
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the inclusion variant (as opposed to the A549-JV subline
that expressed predominantly the NUMB exon 11-
inclusion transcript: see [2], Figure Six C, upper panel,
lane 14). In the transformed but non-tumourigenic
BEAS-2B bronchial epithelial cells, we predicted a lower
NUMB exon 11 inclusion to exclusion ratio, based on the
previously reported observations that the ratio of NUMB
exon 11 inclusion to exon 11 exclusion is higher in lung
cancer than in normal cells [19] and our hypothesis that
the RBM10v1(V354del) isoform is more prevalent in can-
cer cells. As shown in Figure 3B, the BEAS-2B cells did
indeed have the lowest NUMB exon 11 inclusion to ex-
clusion ratio of the four cell lines examined. Finally, as
expected, and previously shown by Bechara et al. [2],
HeLa cells had a clearly higher inclusion to exclusion ex-
pression ratio. The only unexpected observation from this
cell line RNA analysis was the high level of the NUMB
exon 11 exclusion variant in the A549-LS cells, consider-
ing they are a lung cancer cell line. Determination of the
relative expression levels of the transcripts encoding
RBM10v1(V354) and RBM10v1(V354del) isoforms in this
subline would help to resolve this conundrum.
Discussion
RBM10 is an apoptosis regulatory protein [20] and its
paralogue, RBM5 functions in the same capacity, but has
the added ability to regulate the cell cycle [21,22]. Based
on the findings of Bechara et al. [2], it appears that
RBM10 is also able to regulate the cell cycle, via the
NOTCH signaling pathway [2]. Is the regulation of
RBM10v1(V354) versus RBM10v1(V354del) alternative
splicing a means by which normal cells temporarily
modulate proliferation prior to a repair versus apoptosis
event? Have cancer cells hijacked this alternative splicing
mechanism as one means of circumventing proliferation
controls? Of the mutations identified so far in pancreatic
cancer and NSCLCs, none occurs at this site to per-
manently generate the minus valine isoform, except
the mutation described by Bechara et al. [2] in a lung
adenocarcinoma cell line (see Table 1). It is therefore diffi-
cult to predict how important the regulation of this alter-
native splicing event is to cancer initiation and/or
progression. We have initiated studies to more thoroughly
characterise the expression of transcripts encoding the
two RBM10v1 and RBM10v2 isoforms in primary lung
cancer specimens. Additional studies relating to protein
expression are also warranted, as are studies concerning
the regulation of this expression.
In an attempt to align our observations with those of
Bechara et al. [2] and Wang et al. [3] we propose a model
to explain how changes in RBM10v1 splicing might be
predicted to regulate NUMB splicing. The model takes
into consideration the following observations. Firstly,overexpression of RBM10 correlates with NUMB exon 11
exclusion [2,3]. Secondly, in lung cancer there is preferen-
tial expression of the NUMB exon 11 inclusion variant.
Thirdly, in lung cancer RBM10 is highly expressed [10],
but while in our A549, HeLa, BEAS-2B and GLC20 cells
transcripts encoding both RBM10v1 isoforms were ob-
served, there was two-fold more RBM10v1(V354del) than
RBM10v1(V354) in the GLC20 SCLC cells. Our model
does not attempt to reconcile the somewhat conflicting
binding data previously reported [2,3].
Our model, depicted in Figure 3C, posits that RBM10v1
(V354) and RBM10v1(V354del) are both expressed in
normal cells, but that in cancers RBM10v1(V354del) is
preferentially expressed. RBM10v1(V354) and RBM10v1
(V354del) are both capable of interacting with pre-
mRNA, and do so in the vicinity of the upstream intronic
3′-splice site of the alternate exon. RBM10v1(V354del),
however, has a higher affinity interaction with pre-mRNA
than RBM10v1(V354) (resulting from its ability to form
the second α-helix within RRM2). In its capacity as a
higher affinity binder, RBM10v1(V354del) is able to func-
tion as an auxiliary splicing factor. As for RBM10v1
(V354), disruption of the second α-helical structure
within RRM2 generates an RBM10v1 isoform that inter-
acts with the same pre-mRNA as RBM10v1(V354del) but
in a manner that impedes splicing. As a result of either
less efficient or lower affinity binding or an inability to
optimally interact with other auxiliary/splicing factors,
expression of RBM10v1(V354) functions to increase the
splicing of the alternative transcript. In our model, the
increase in the NUMB exon 11 inclusion transcript that
is associated with downregulation of RBM10 results from
the presence of reduced levels of the competing, less effi-
cient binding, RBM10v1(V354) isoform and consequently
more binding of the higher affinity RBM10v1(V354del)
isoform, resulting in more of the NUMB exon 11 inclu-
sion product. According to our model, therefore, alterna-
tive splicing regulation by RBM10 depends not only on
the ratio of RBM10v1(V354) to RBM10v1(V354del), but
on the total levels of RBM10v1 protein as well.
Exactly how the structural change associated with a
valine insertion at amino acid 354 of RBM10v1 results in
splicing changes is unknown. Multiple binding motifs
have been identified for RBM10 [2] as have multiple po-
tential binding regions within pre-mRNA [2,3], suggest-
ing that interaction of RBM10 with pre-mRNA targets
may be a dynamic and flexible phenomenon. And while
expression of RBM10 is more frequently associated with
alternate exon exclusion [1-3,23], it is also associated
with alternate exon inclusion [2,3]. Perhaps binding and
function of RBM10 is more influenced by tertiary struc-
ture than primary sequence of the protein, and the mul-
tiple sequence motifs and binding regions identified
within pre-mRNAs reflect interactions with different
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conformation.
To note just prior to submission of this manuscript,
Ensembl (which had not, at least during the course of
this investigation, listed RBM10v1(V354del) in its data-
base) removed the RBM10v2(V277del) isoform, thereby
eliminating all reference to the minus-valine isoforms.
The minus valine isoforms are those which form the
classic α-helical structure associated with the RRM do-
mains (as shown herein), RNA transcripts encoding the
minus valine isoform of RBM10v1 exist in multiple cell
types (as shown herein), and functional studies demon-
strate the apoptotic regulatory ability [20] and alternative
splicing ability [2] of RBM10v1(V354del). We therefore
suggest that the alternative splicing of RBM10v1, and
likely RBM10v2, is a regulated event worthy of consider-
ation in functional studies.
Materials and methods
Cell culture and differentiation
GLC20 cells were kindly provided by Charles Buys (Uni-
versity of Groningen, The Netherlands). Cells were cul-
tured in RPMI supplemented with 10% fetal bovine
serum (FBS). JKM1 [24], Jurkat Clone E6 [25], MCF-7
[26], MDA-MB-231 [27] and TF-1 cells [25] were grown
as previously described. A549 (from ATCC) and HeLa cells
(provided by Hoyun Lee, AMRIC) were grown in DMEM/
F-12 medium supplemented with 10% FBS. TK6 cells (pro-
vided by Elliot Drobetsky, University of Montreal) were
grown in DMEM/F-12 medium supplemented with 10%
fetal horse serum. BEAS-2B cells (purchased from ATCC)
were grown in LHC-9 medium, on plates pre-coated with
0.01 mg/ml fibronectin, 0.03 mg/ml collagen and 0.01 mg/
ml bovine serum albumin. Media and sera were purchased
from Life Technologies (Burlington, Canada).
Fluorescent in situ hybridization (FISH)
Slides were prepared from a cell suspension using
standard cytogenetic techniques. Slides were denatured
at 75°C for 2 mins and hybridized overnight at 37°C
with Spectrum Green (X chromosome) and Spectrum Red
(Y chromosome) (Vysis, Abbott Molecular, Mississauga,
Canada). Following hybridization the slides were washed
in 0.4×SSC/0.3% NP40 at 73°C for 2 mins, then 2.0×SSC/
0.1% NP40 at 23°C for 1 min. Slides were dried in the
dark then stained with Vysis DAPI II and the coverslips
applied. Images were captured using an Olympus BX60
microscope equipped with a mercury bulb and camera.
Images were processed with Cytovision software from
Genetix.
RNA extraction, reverse-transcription and PCR
RNA was isolated from cell pellets using Tri-Reagent
(Molecular Research Center, Inc., Cedarlane, Burlington,Canada). Reverse transcription was carried out using
1 μg of RNA, and MMLV (for expression level reactions)
or SuperScript II (for sequencing) reverse transcriptase
(Life Technologies). Amplification of cDNA by polymerase
chain reaction (PCR) was performed using gene-specific
primers RBM10F and RBM10RS (exon 4 spanning) [27]
(Figure 1Bi) or RBM10v1/v2R (also exon 4 spanning) [20]
(Figure 1Bii), NUMBF(exon10): 5′-TAGAAGGGGAGG
CAGAGAGC-3′ and NUMBR(exon12): 5′-CTCAGAGG
GAGTACGTCTAT-3′ and GAPDH [28] (all primers pur-
chased from AlphaDNA, Montreal, Canada). End-point
PCR reaction conditions: (1) 95°C for 5 minutes, (2) gene-
specific cycle number (40 cycles for RBM10, 28 and 40 cy-
cles for NUMB, and 19 (Figure 3Bi) or 25 (Figures 1Bii
and 3Bii) cycles for GAPDH) of 95°C for 30 seconds, 62°C
(RBM10F + RS), 55°C (RBM10F + v1/v2R), 61°C (NUMB),
59°C (GAPDH) for 30 seconds, 72°C for 45 seconds, and
(3) 72°C for 10 minutes. The samples were visualized fol-
lowing electrophoresis through a 2% (40 mM Tris-acetate,
10 mM EDTA, pH 8.0) (TAE) agarose gel containing
SYBR®safe DNA gel stain (Life Technologies).
For sequencing of full-length RBM10, nested PCR was
carried out, using RBM10FNhe1: 5′-CTA GCT AGC
TAG TGG CTG GGA AGT GAA ACG GAG CCA
GCG-3′ and RBM10RL: 5′-TGG CTG GGG AGT GGG
CTG G-3′ primers for Reaction 1 and RBM10FNhe1
and RBM10RHindIII: 5′-CCC AAG CTT GGC TGG
GCC TCG TTG AAG CG-3′ primers for Reaction 2,
Platinum Pfx Polymerase (Life Technologies) and 5 μl of
Reaction 1 as template for Reaction 2. PCR reaction con-
ditions: Reaction 1: (1) 95°C for 2 minutes, (2) 18 cycles of
94°C for 10 seconds, 66°C for 1 minute, 68°C for 3 minutes;
Reaction 2: (3) 22 cycles of 94°C for 10 seconds, 62°C for
1 minute, 68°C for 3 minutes, (4) 72°C for 5 minutes.
Immunoblotting
Western blotting was carried out as previously described
[20]. RBM10 antibody was used at a dilution of 1:500. The
in vitro transcription/translation reactions were carried
out using a TNT® T7 Quick Coupled Transcription/
Translation Kit (Promega, through Fisher Scientific, Nepean,
Canada), and plasmid constructs pcDNA3.RBM10v1 or
pcDNA3.RBM10v2 [20].
Sequencing
Full-length RBM10v1 and RBM10v2 amplicons were sepa-
rated by agarose gel electrophoresis (note, no full-length
RBM10v2 amplicon was detectable in the GLC20 cells)
and cDNA was excised using a QIAquick gel extraction
kit (Qiagen, Toronto, Canada). DNA quantity (absorbance
at 260 nanometers (nm)) and purity (ratio of the absorb-
ance at 260 and 280 nm) were determined using a Nano-
Drop 2000C spectrophotometer (Fisher Scientific, Ottawa,
Canada), and the samples were sent for sequencing.
Tessier et al. BMC Research Notes  (2015) 8:46 Page 10 of 11Samples were sequenced, using the Sanger technique,
by the MOBIX Lab - DNA Sequencing and Oligo Syn-
thesis Facility (McMaster University, Hamilton,
Canada). Internal primers (sequences available upon re-
quest) were generated by MOBIX. Bi-directional, over-
lapping sequence reads of ~600 bp were generated, as
detailed in Figure 1D.
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